Plain-English translation of NCT06514001 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Alzheimer Disease research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called that is injected into the bloodstream and then tracked using special eye imaging. The goal is to see whether this medication can help doctors diagnose Alzheimer's disease by revealing specific patterns in the back of the eye (the retina). Researchers want to understand whether this approach is safe and whether it could become a useful diagnostic tool.
Currently, diagnosing Alzheimer's disease often requires expensive brain scans. This medication could offer a simpler, less costly way to detect the disease by using eye imaging instead, which might make earlier diagnosis more accessible to patients.
You likely qualify if…
You likely don't qualify if…
You will visit the study site for a single day visit. Before receiving the medication, the study team will examine your eyes and take retinal images. You will then receive a single injection of the medication through an IV line. After that, the team will monitor you for safety, take more retinal images, and draw blood samples to understand how the medication moves through your body. The entire visit typically takes several hours.
AI-generated summary from trial data · Jul 1, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
Amydis Inc.
Enrollment target
~25 participants
Started
March 2025
Primary completion
September 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in February 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Matthew Lehman
Amydis Inc.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.